Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.

Trial Details

NCT ID
NCT07018050
Phase
PHASE2
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • QLS32015
  • Pomalidomide
  • Dexamethasone
  • QL2109 or Daratumumab
  • Bortezomib
  • Lenalidomide
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Diagnosis of multiple myeloma confirmed according to the 2016 International Myeloma Working Group (IMWG) diagnostic criteria;
  • Prior therapy: Relapsed, progressed, or intolerant to ≥1 prior line of anti-multiple myeloma therapy;
  • Measurable disease at screening, defined by at least one of the following:
  • Serum M-protein ≥1.0 g/dL (10 g/L);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →